| |
Placebo
|
MFGM
|
ANOVA (G × T)
|
---|
P
-value
|
---|
RMS, mV
|
baseline
|
0.133 ± 0.017
|
0.145 ± 0.019
|
0.778
|
5 weeks
|
0.156 ± 0.016
|
0.172 ± 0.019
|
10 weeks
|
0.153 ± 0.014
|
0.175 ± 0.022
|
Δ 10 weeks (%)a
|
27.3 ± 10.6d
|
27.1 ± 10.4d
|
MFCV, m/sec
|
baseline
|
5.91 ± 0.39
|
5.77 ± 0.32
|
0.046
|
5 weeks
|
5.02 ± 0.48
|
5.43 ± 0.22
|
10 weeks
|
4.17 ± 0.45b
|
5.58 ± 0.39c
|
Δ 10 weeks (%)a
|
- 27.2 ± 8.2d
|
1.1 ± 8.9c
|
- MFGM, milk fat globule membrane; ANOVA, analysis of variance.
- Values are means ± SEM of 16 (placebo group [women, n = 7; men, n = 9]) and 19 (MFGM group [women, n = 11; men, n = 8]) subjects for RMS and 12 (placebo group [women, n = 5; men, n = 7]) and 16 (MFGM group [women, n = 10; men, n = 6]) subjects for MFCV, respectively.
-
aThe value is the percentage change from the baseline to 10 weeks. Repeated-measures ANOVA for the group-by-time interaction (G × T) during the interventional period. bThere was a significant difference from the baseline during the interventional period, as determined using the Bonferroni test (P < 0.05). cThere was a significant difference between the two groups in results of the unpaired t-test (P < 0.05). dThere was a significant difference from the baseline to 10 weeks in results of the paired t-test (P < 0.05).